Compare Humana Inc (HUM) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Jumia Technologies AG - ADR — how do they compare? Humana Inc trades at $374.25 (market cap $46.31B), while Jumia Technologies AG - ADR trades at $5.97 (market cap $743.12M). The key difference: Humana Inc is far larger — about 62.3× Jumia Technologies AG - ADR's market cap, and Humana Inc pays a 0.92% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| HUM | JMIA | |
|---|---|---|
Market Cap | $46.31B | $743.12M |
Sector | Health | Consumer Cyclical |
52-Week High | $409.42 | $14.60 |
52-Week Low | $163.67 | $5.69 |
Enterprise Value | $53.67B | $690.21M |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
JMIA trades at $6.19, up 8.79% today, but remains in a bearish technical trend with mixed signals from moving averages and oscillators. Fundamentally, the company shows improving revenue trends ($189M in 2025) and narrowing losses, though it continues to post negative net income margins (-30.79%). Recent news highlights management's focus on achieving profitability by 2027 through strategic partnerships and expansion initiatives.
While analyst consensus remains strongly bullish (71% buy ratings), JMIA faces significant execution risks in its path to profitability. The stock presents speculative upside potential if the company can deliver on its 2027 profitability targets, but investors should weigh the substantial losses against the promising revenue growth trajectory in African e-commerce markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
